🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yinglu Zhou

Harvard University

ORCID: 0000-0001-6276-635X

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.518Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574
Top 37%
0.518DataRank
Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

Papers

Driven by 9 papers — median percentile 63. Top paper: “Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy”.

Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy

European Urology(2022)10.1016/j.eururo.2021.12.039
N/A
0.763DataRank · unranked
161 citations

William Butler, Yinglu Zhou, Hong Zhang, Lu Tang, Kathryn Perkinson +6 more

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574
Top 37%
0.518DataRank
Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance

npj Precision Oncology(2023)10.1038/s41698-023-00363-2
N/A
0.470DataRank · unranked
22 citations

Colin T. McDowell, Qing Yang, Yiping He, Yue Zhao, J. Spencer Hauck +7 more

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016006
N/A
0.385DataRank · unranked
12 citations

Yinglu Zhou, Mariia Mikhaleva, Daniel Choi, Stacey M. Fernandes, Philippe Armand +20 more

The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer

Molecular Cancer Research(2022)10.1158/1541-7786.mcr-22-0627
N/A
0.360DataRank · unranked
10 citations

Yinglu Zhou, Giuseppe Nicolò Fanelli, Konrad H. Stopsack, Michelangelo Fiorentino, Giorgia Zadra +5 more

Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer

Oncogene(2022)10.1038/s41388-021-02155-z
N/A
0DataRank · unranked
28 citations

Bing Zhao, William Butler, Huan Xu, Nan Song, Xufeng Chen +12 more

Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer

The Journal of Pathology(2023)10.1002/path.6063
N/A
0DataRank · unranked
19 citations

Lingfan Xu, Yinglu Zhou, Qing Cheng, J. Spencer Hauck, Yiping He +10 more

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Blood Advances(2022)10.1182/bloodadvances.2022008447
N/A
0DataRank · unranked
80 citations

Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen P. Martindale +20 more

Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance

Nature Cancer(2022)10.1038/s43018-022-00431-9
N/A
0DataRank · unranked
152 citations

Choushi Wang, Yunguan Wang, Yaru Xu, Xiaoling Li, Nickolas A. Johnson +21 more